Deutsche Bank started coverage on shares of Humana (NYSE:HUM) in a research report report published on Thursday morning, BenzingaRatingsTable reports. The brokerage issued a hold rating on the insurance provider’s stock.

A number of other research firms have also recently weighed in on HUM. JPMorgan Chase & Co. raised their price target on shares of Humana from $288.00 to $322.00 and gave the company an overweight rating in a report on Thursday, August 1st. Morgan Stanley raised their price target on shares of Humana from $315.00 to $342.00 and gave the company an overweight rating in a report on Friday, August 23rd. ValuEngine cut shares of Humana from a hold rating to a sell rating in a report on Wednesday. UBS Group raised their price target on shares of Humana from $266.00 to $317.00 and gave the company a neutral rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies raised their price target on shares of Humana from $315.00 to $341.00 and gave the company an overweight rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company. Humana presently has an average rating of Buy and an average price target of $341.95.

Shares of HUM traded up $6.31 during midday trading on Thursday, hitting $274.69. The stock had a trading volume of 939,733 shares, compared to its average volume of 1,266,545. Humana has a 1 year low of $225.65 and a 1 year high of $355.88. The firm has a market cap of $37.40 billion, a PE ratio of 18.88, a price-to-earnings-growth ratio of 1.20 and a beta of 0.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The stock’s 50 day moving average is $287.14 and its 200 day moving average is $269.38.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.24 by $0.81. The company had revenue of $16.25 billion for the quarter, compared to the consensus estimate of $15.88 billion. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm posted $3.96 EPS. As a group, equities research analysts expect that Humana will post 17.63 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Friday, September 27th. Humana’s dividend payout ratio (DPR) is presently 15.12%.

In related news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.54% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of HUM. Maverick Capital Ltd. raised its position in Humana by 150.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock worth $411,408,000 after buying an additional 932,778 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Humana by 4,141.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 706,911 shares of the insurance provider’s stock valued at $187,543,000 after purchasing an additional 690,246 shares in the last quarter. PointState Capital LP purchased a new position in shares of Humana during the 2nd quarter valued at approximately $180,507,000. Marshall Wace North America L.P. increased its holdings in shares of Humana by 6,921.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 536,275 shares of the insurance provider’s stock valued at $142,273,000 after purchasing an additional 528,637 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Humana during the 2nd quarter valued at approximately $115,680,000. 92.90% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: Momentum Investing

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.